Your Article Summary
See Latest ArticlesStrativa's development partner, bioalliance pharma, submits loramyc nda
Par Pharmaceutical, 06/17/09
Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. , announced that its development partner, BioAlliance Pharma, has submitted a New Drug Application to the Food and Drug Administration for Loramyc (miconazole Lauriad) 50mg mucoadhesive buccal tablets, as planned. If approved, Strativa could launch Loramyc in the second half of 2010.
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Sanofi-aventis to acquire Oenobiol, French leader in nutritional beauty supplements
Sanofi-aventis, 11/02/09
Nabi Biopharmaceuticals Completes Sale of PentaStaph to GlaxoSmithKline PLC
Nabi Biopharmaceuticals, 11/05/09
New Drug Application Filed for Eldecalcitol, An Active Vitamin D3 Derivative
Chugai Pharmaceutical Co., 11/04/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09
Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
Lundbeck, 11/02/09
Forest Laboratories, Inc. and Gedeon Richter Announce Positive Results from a Phase IIb Study of Cariprazine for the Treatment of Schizophrenia
Forest Laboratories, 10/29/09